Credit rating agency, India Ratings and Research (Ind-Ra) in its latest report has said that the Indian pharmaceutical market (IPM) continued to deliver mid-single digit growth for the last three consecutive months at 5.3% in September 2024. The report noted that this is because of price growth (5.3% yoy) and new launches (2.4% yoy). However, it said the volume growth (negative 2.4% yoy) remained weak.
According to the report titled ‘Pharma Pulse - September 2024: Mid-Single Digit Growth Continues’, key therapies such as cardiac, anti-infectives, anti-diabetic, and central nervous system outperformed the IPM growth. However, it stated that gastro, vitamins and respiratory witnessed lower growth in September 2024.
Ind-Ra further said that during January to September 2024, the IPM reported average growth of 7.7% yoy (monthly) with average volume growing negative 0.9% yoy. Further, the rating agency is expecting the IPM growth to be 8%-9% yoy in FY25 (FY24: 6.5% yoy; FY23: 9.9% yoy).